In this article, we will discuss Olaparib (Clinical Trials Experience-6). So, let’s get started.
Treatment of Advanced gBRCAm Ovarian Cancer After 3 or More Lines of Chemotherapy
Pooled data (1)
Treatment with Olaparib (capsule formulation) as monotherapy was studied in 223 patients (pooled from 6 studies) with gBRCAm advanced ovarian cancer who had received 3 or more prior lines of
chemotherapy. Adverse reactions led to dose interruption in 40% of patients, dose reduction in 4% of patients, and discontinuation in 7% of patients.